NCT06032533 Remote Ischemic Conditioning in Aneurysmal SAH
| NCT ID | NCT06032533 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aarhus University Hospital |
| Condition | Subarachnoid Hemorrhage, Aneurysmal |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-09-09 |
| Primary Completion | 2027-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-09-09 with a primary completion date of 2027-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to examine the effect of limb occlusion therapy (remote ischemic conditioning, RIC) in subjects with aneurysmal subarachnoid hemorrhage. The main question it aims to answer is whether RIC can improve long-term recovery in participants with aneurysmal subarachnoid hemorrhage. Researchers will compare levels of functional independence in participants in the RIC-group to participants in the sham-group.
Eligibility Criteria
Inclusion Criteria: * Aneurysmal subarachnoid hemorrhage confirmed by computed tomography (CT) with aneurysm origin confirmed by computed tomography angiography (CTA) or digital subtraction angiography (DSA) * Aneurysmal subarachnoid hemorrhage symptom-onset ≤ 3 days * Aneurysm protected by clipping or coiling * Independent in daily living before symptom onset (mRS ≤ 2) Exclusion Criteria: * Subarachnoid hemorrhage caused by a lesion other than cerebral aneurysm * Symptomatic vasospasm at the time of enrollment * Previous cerebral lesion e.g. symptomatic cerebral infarction (\>2cm), multiple sclerosis, symptomatic intracerebral hemorrhage, tumour, prior neurosurgery (excluding prior clipping or coiling of cold aneurysms without complications). * History of severe peripheral vascular disease or signs of severe peripheral vascular disease on physical examination * History of deep vein thrombosis or signs of deep vein thrombosis on physical examination * Kidney involvement or prior kidney disease with an estimated glomerular filtration rate (eGFR) below safe levels for contrast infusion in relation to CT-perfusion. * Pregnancy (Women of child-bearing age will have serum-Humane Choriogonadotropine taken prior to final inclusion. If pregnancy cannot be ruled out,the patient can't be included. Women with a safe birth control method will be encouraged to use this method during the entire period of active treatment.) * Concomitant other acute life-threatening medical or surgical condition
Contact & Investigator
Grethe Andersen, Prof., MD
PRINCIPAL INVESTIGATOR
Department of Neurology, Aarhus University Hospital
Frequently Asked Questions
Who can join the NCT06032533 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Subarachnoid Hemorrhage, Aneurysmal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06032533 currently recruiting?
Yes, NCT06032533 is actively recruiting participants. Contact the research team at kimoer@rm.dk for enrollment information.
Where is the NCT06032533 trial being conducted?
This trial is being conducted at Aarhus N, Denmark.
Who is sponsoring the NCT06032533 clinical trial?
NCT06032533 is sponsored by Aarhus University Hospital. The principal investigator is Grethe Andersen, Prof., MD at Department of Neurology, Aarhus University Hospital. The trial plans to enroll 100 participants.